Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Free Cash Flow (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Free Cash Flow for 16 consecutive years, with $13.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 108.95% year-over-year to $13.3 million, compared with a TTM value of $319.0 million through Dec 2025, up 165.54%, and an annual FY2025 reading of $156.9 million, up 133.58% over the prior year.
  • Free Cash Flow was $13.3 million for Q4 2025 at Arrowhead Pharmaceuticals, up from -$1.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $462.3 million in Q1 2025 and bottomed at -$225.3 million in Q2 2024.
  • Average Free Cash Flow over 5 years is -$23.1 million, with a median of -$50.3 million recorded in 2021.
  • The sharpest move saw Free Cash Flow surged 922.94% in 2021, then plummeted 214.78% in 2022.
  • Year by year, Free Cash Flow stood at -$67.1 million in 2021, then plummeted by 33.5% to -$89.6 million in 2022, then plummeted by 44.18% to -$129.1 million in 2023, then dropped by 15.27% to -$148.8 million in 2024, then soared by 108.95% to $13.3 million in 2025.
  • Business Quant data shows Free Cash Flow for ARWR at $13.3 million in Q4 2025, -$1.9 million in Q3 2025, and -$154.7 million in Q2 2025.